**Abstract**

As Alzheimer disease therapeutics candidate, we have developed SAK3 (Ethyl 2',3'-dyhydro-8-methyl-2',4-dioxo-2-peperidinospiro\[2-cyclopentene-1,3'-imidazo\[1,2-a\]-pyridine\]-3-carboxylates) (PCT/JP2013/051388). SAK3 stimulates T-type voltage-gated Ca^2+^ channels (T-VGCC) in mouse cortical slices (Moriguchi et al., J Neurochem 2012;121:44--53). We also reported that SAK3 stimulates acetylcholine release and promotes long-term potentiation in mouse hippocampus (Neuroscience 2014 abstract 265.21). We here tested whether SAK3 reduced amyliod beta (1--42) accumulation in Alzheimer model (APP23) mice. APP23 mice aged 6 and 9 months were treated for two or three months with SAK3 (0.5mg/kg, p.o.) and measured amyliod beta (1--42) levels in both soluble and insoluble fractions from APP23 mouse cortex. The chronic administration significantly reduced the amyliod beta (1--42) levels. Consistent with the reduced amyliod beta (1--42) levels, the numbers of amyloid plaques assessed by thioflavin staining were significantly reduced by the chronic SAK3 treatment. Furthermore, the cognition assessed by novel object recognition task was improved by the chronic administration. Using LC/MS/MS system, we established high sensitivity quantification system in blood to obtain proof-of-concept of SAK3 safety in human. Taken together, the novel T-type calcium channel stimulator SAK3 restored cognition ability in APP23 mice and reduced the amyliod beta (1--42) accumulation/aggregation. However, further extensive studies are required to elucidate the underlying mechanism.
